Venter C P, Joubert P H
S Afr Med J. 1986 Mar 1;69(5):286-7.
A single-blind placebo-controlled study was conducted on black hypertensive patients with a once-daily dose of penbutolol (Betapressin; Hoechst); a non-selective beta-blocker. Of 29 patients who participated in a 4-week run-in period, 18 were entered into a 20-week trial of the active medication. Fourteen patients were adequately controlled, 2 did not respond satisfactorily and 2 dropped out of the study. On cessation of therapy all patients became hypertensive again. No significant changes in mean heart rates were observed during active medication as opposed to placebo. Penbutolol can therefore be used as a sole antihypertensive agent in blacks.
对黑人高血压患者进行了一项单盲安慰剂对照研究，每天服用一次喷布洛尔（倍他洛尔；赫斯特公司生产），这是一种非选择性β受体阻滞剂。在参与为期4周导入期的29名患者中，18名进入了为期20周的活性药物试验。14名患者血压得到充分控制，2名患者反应不令人满意，2名退出研究。治疗停止后，所有患者血压再次升高。与安慰剂相比，服用活性药物期间平均心率未观察到显著变化。因此，喷布洛尔可作为黑人患者的单一抗高血压药物。
